Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles

I.G Kondrasheva,P.Ye Gambaryan,A.A Kamensky,G.G Barsegyan,T.A Antipova,A.A Guseva

doi:10.4236/eng.2012.410b007

Abstract

Inclusion of L-DOPA, the standard Parkinson’s disease medication, into polymeric particles (PLGA) results in optimization the drug metabolism and increasing its bioavailability, significantly increases of physical endurance, better coordination and lower anxiety in Wistar rats, when chronically administered nasally.

Highlights

Nasal administration of medications is a well known and currently widely applicable method of administration of a number of broad-spectrum drugs, both locally and systemically acting, the interest in which, as a non-invasive method of administration drugs, deepens on [1]
Drugs can be transported from nasal cavity into the central nervous system (CNS) without involving the blood circulatory system of nasal-cavity lining mucosa, by extracellular way – along the trifacial nerve and the olfactory nerve
Optimizing the drug metabolism and increasing its bioavailability and potency are possible, if it is included into nanoparticles based on poly(lactic-co-glycolic acid) (PLGA), a biodegradable and non-toxic polymer

Summary

Introduction

Nasal administration of medications is a well known and currently widely applicable method of administration of a number of broad-spectrum drugs, both locally and systemically acting, the interest in which, as a non-invasive method of administration drugs, deepens on [1]. Olfactory nerve sheathes do not have blood-brain barriers, and the drug can directly enter the brain [2,3,4,5] This fact is the focus of attention, since it provides new opportunities in treating CNS diseases, neurodegenerative brain diseases, such as Parkinson’s disease or Alzheimer’s disease [6]. The purpose of this research is the estimation of efficacy and safety of the nasal administration of L-DOPA, the precursor of the dopamine neurotransmitter, in form of a nanoparticle medication (“Nano-L-DOPA”) developed on the basis of poly(lactic-co-glycolic acid) (PLGA) for modulating (increasing) the exercise performance of rats Wistar, as compared to the efficacy and safety of L-DOPA, the initial standard medication

Objectives

Methods

Results